Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details)

v3.19.2
Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Disaggregation of Revenue [Line Items]        
Total Revenue $ 5,332 $ 11,691 $ 13,877 $ 15,843
Seattle Genetics        
Disaggregation of Revenue [Line Items]        
Total Revenue 504 2,425 1,429 2,731
AstraZeneca        
Disaggregation of Revenue [Line Items]        
Total Revenue 3,888 6,390 9,908 8,937
Servier        
Disaggregation of Revenue [Line Items]        
Total Revenue 940 1,419 2,540 2,627
Other        
Disaggregation of Revenue [Line Items]        
Total Revenue $ 0 $ 1,457 $ 0 $ 1,548